Compare American Airlines Group Inc (AAL) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs Citius Pharmaceuticals Inc — how do they compare? American Airlines Group Inc trades at $14.94 (market cap $10.55B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: American Airlines Group Inc is far larger — about 527.2× Citius Pharmaceuticals Inc's market cap, and American Airlines Group Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AAL | CTXR | |
|---|---|---|
Market Cap | $10.55B | $20.01M |
Sector | Industrials | Health |
52-Week High | $18.15 | $1.82 |
52-Week Low | $10.18 | $0.48 |
Enterprise Value | $38.51B | $16.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Airlines (AAL) trades at $14.94, down 0.43% with a bearish technical signal. The company shows mixed fundamentals with strong revenue growth but negative net income margin (-0.56%) and elevated P/E of 43.73. Recent Q2 2026 earnings beat expectations with $0.15 EPS versus $0.03 expected, while Q4 2025 missed estimates. Cash flow remains positive with $154M net cash flow in 2025. Analyst consensus is mixed with 44.7% buy ratings and $19.63 price target, representing 31% upside.
AAL presents a turnaround opportunity with premium revenue growth and debt reduction, but faces significant headwinds from fuel costs and negative equity. The stock trades below analyst targets but requires sustained profitability improvement to justify current valuation multiples. Key risks include fuel price volatility and competitive pressure in the airline industry.
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
